OSE Immunotherapeutics SA (OSE.PA)
EUR 7.17
(-1.38%)
EUR 7.17
(-1.38%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -23 Million EUR | -29.52% |
| 2022 | -17.76 Million EUR | -5.4% |
| 2021 | -16.85 Million EUR | -1.78% |
| 2020 | -16.55 Million EUR | -255.87% |
| 2019 | -4.65 Million EUR | -184.74% |
| 2018 | 5.49 Million EUR | 152.27% |
| 2017 | -10.5 Million EUR | -150.82% |
| 2016 | 20.66 Million EUR | 470.09% |
| 2015 | -5.58 Million EUR | -96.97% |
| 2014 | -2.83 Million EUR | -1034.0% |
| 2013 | -250 Thousand EUR | 82.59% |
| 2012 | -1.43 Million EUR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 57.17 Million EUR | 0.0% |
| 2023 Q2 | -11.86 Million EUR | 0.0% |
| 2023 Q4 | -11.14 Million EUR | 0.0% |
| 2023 FY | -23 Million EUR | -29.52% |
| 2022 Q2 | -1.97 Million EUR | 0.0% |
| 2022 Q4 | -15.78 Million EUR | 0.0% |
| 2022 FY | -17.76 Million EUR | -5.4% |
| 2021 FY | -16.85 Million EUR | -1.78% |
| 2021 Q4 | -5.36 Million EUR | 0.0% |
| 2021 Q2 | -11.48 Million EUR | 0.0% |
| 2020 Q4 | -13.44 Million EUR | 0.0% |
| 2020 FY | -16.55 Million EUR | -255.87% |
| 2020 Q2 | -3.11 Million EUR | 0.0% |
| 2019 Q4 | -5.16 Million EUR | 0.0% |
| 2019 Q2 | 514 Thousand EUR | 0.0% |
| 2019 FY | -4.65 Million EUR | -184.74% |
| 2018 FY | 5.49 Million EUR | 152.27% |
| 2018 Q2 | 8.87 Million EUR | 0.0% |
| 2018 Q4 | -3.38 Million EUR | 0.0% |
| 2017 FY | -10.5 Million EUR | -150.82% |
| 2017 Q4 | -4.16 Million EUR | 0.0% |
| 2017 Q2 | -6.34 Million EUR | 0.0% |
| 2016 FY | 20.66 Million EUR | 470.09% |
| 2016 Q4 | -3.84 Million EUR | 0.0% |
| 2016 Q2 | 24.5 Million EUR | 0.0% |
| 2015 FY | -5.58 Million EUR | -96.97% |
| 2015 Q4 | -2.64 Million EUR | 0.0% |
| 2015 Q2 | -2.94 Million EUR | 0.0% |
| 2014 FY | -2.83 Million EUR | -1034.0% |
| 2014 Q4 | -2.18 Million EUR | 0.0% |
| 2014 Q2 | -655 Thousand EUR | 0.0% |
| 2013 Q1 | -61.5 Thousand EUR | 0.0% |
| 2013 Q2 | -123 Thousand EUR | -100.0% |
| 2013 Q3 | -63.5 Thousand EUR | 48.37% |
| 2013 FY | -250 Thousand EUR | 82.59% |
| 2013 Q4 | -127 Thousand EUR | -100.0% |
| 2012 FY | -1.43 Million EUR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| ABIONYX Pharma SA | -3.51 Million EUR | -553.866% |
| ABIVAX Société Anonyme | -147.74 Million EUR | 84.43% |
| Adocia SA | -21.16 Million EUR | -8.7% |
| Aelis Farma SA | -5.07 Million EUR | -352.993% |
| Biophytis S.A. | -17.02 Million EUR | -35.105% |
| Advicenne S.A. | -7.03 Million EUR | -227.165% |
| genOway Société anonyme | 1.56 Million EUR | 1567.426% |
| IntegraGen SA | -171.39 Thousand EUR | -13320.732% |
| Medesis Pharma S.A. | -3.95 Million EUR | -480.959% |
| Neovacs S.A. | -8.74 Million EUR | -163.088% |
| NFL Biosciences SA | -3.74 Million EUR | -514.154% |
| Plant Advanced Technologies SA | 79.16 Thousand EUR | 29155.565% |
| Quantum Genomics Société Anonyme | -3.17 Million EUR | -625.43% |
| Sensorion SA | -22.06 Million EUR | -4.259% |
| Theranexus Société Anonyme | -6.82 Million EUR | -236.895% |
| TME Pharma N.V. | -6.73 Million EUR | -241.493% |
| Valbiotis SA | -7.36 Million EUR | -212.201% |
| TheraVet SA | -1.57 Million EUR | -1364.5% |
| Valerio Therapeutics Société anonyme | -20.34 Million EUR | -13.07% |
| argenx SE | -272.91 Million EUR | 91.571% |
| BioSenic S.A. | -28.77 Million EUR | 20.067% |
| Celyad Oncology SA | -8.44 Million EUR | -172.289% |
| DBV Technologies S.A. | -67.26 Million EUR | 65.805% |
| Galapagos NV | 211.69 Million EUR | 110.866% |
| Genfit S.A. | -28.89 Million EUR | 20.388% |
| GeNeuro SA | -14.75 Million EUR | -55.879% |
| Hyloris Pharmaceuticals SA | -15.38 Million EUR | -49.564% |
| Innate Pharma S.A. | -7.57 Million EUR | -203.871% |
| Inventiva S.A. | -110.42 Million EUR | 79.169% |
| MaaT Pharma SA | -19.71 Million EUR | -16.666% |
| MedinCell S.A. | -25.03 Million EUR | 8.128% |
| Nanobiotix S.A. | -39.7 Million EUR | 42.058% |
| Onward Medical N.V. | -36.18 Million EUR | 36.422% |
| Oryzon Genomics S.A. | -3.35 Million EUR | -586.054% |
| Oxurion NV | -18.96 Million EUR | -21.266% |
| Pharming Group N.V. | -9.75 Million EUR | -135.769% |
| Poxel S.A. | -35.09 Million EUR | 34.446% |
| GenSight Biologics S.A. | -26.22 Million EUR | 12.269% |
| Transgene SA | -22.32 Million EUR | -3.023% |
| Financière de Tubize SA | 88.15 Million EUR | 126.095% |
| UCB SA | 343 Million EUR | 106.706% |
| Valneva SE | -101.42 Million EUR | 77.321% |
| Vivoryon Therapeutics N.V. | -28.34 Million EUR | 18.838% |